Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis.
Cortese R., Battaglini M., Prados F., Gentile G., Luchetti L., Bianchi A., Haider L., Jacob A., Palace J., Messina S., Paul F., Marignier R., Durand-Dubief F., de Medeiros Rimkus C., Apostolos Pereira SL., Sato DK., Filippi M., Rocca MA., Cacciaguerra L., Rovira À., Sastre-Garriga J., Arrambide G., Liu Y., Duan Y., Gasperini C., Tortorella C., Ruggieri S., Amato MP., Ulivelli M., Groppa S., Grothe M., Llufriu S., Sepulveda M., Lukas C., Bellenberg B., Schneider R., Sowa P., Celius EG., Pröbstel A-K., Granziera C., Yaldizli Ö., Müller J., Stankoff B., Bodini B., Barkhof F., Ciccarelli O., De Stefano N., MAGNIMS Study Group None.
OBJECTIVE: To evaluate: (1) the distribution of gray matter (GM) atrophy in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD), and relapsing-remitting multiple sclerosis (RRMS); and (2) the relationship between GM volumes and white matter lesions in various brain regions within each disease. METHODS: A retrospective, multicenter analysis of magnetic resonance imaging data included patients with MOGAD/AQP4+NMOSD/RRMS in non-acute disease stage. Voxel-wise analyses and general linear models were used to evaluate the relevance of regional GM atrophy. For significant results (p